EGL-001

DRUG2 trials

Sponsors

Egle Therapeutics

Conditions

Advanced and/or Metastatic Solid TumorsSolid Tumor, Adult

Phase 1

First-in-human Phase 1/2 Trial of EGL-001 in Adult Patients with Selected Advanced and/or Metastatic Solid Tumors (Protocol Number : EGL-121)

RecruitingCTIS2024-512921-10-00

Egle TherapeuticsAdvanced and/or Metastatic Solid Tumors

Start: 2024-09-27Target: 62Updated: 2025-12-19

First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors

RecruitingNCT06622486

Egle TherapeuticsSolid Tumor, Adult

Start: 2024-09-27End: 2027-01-23Target: 50Updated: 2024-11-07

Related Papers

EGL-121, a first-in-human phase 1/2 trial of EGL-001 in adult patients with selected advanced and/or metastatic solid tumors.

Journal of Clinical Oncology2025-05-281 citations

Abstract 6080: Preferential tumor uptake and retention of EGL-001, an anti-CTLA4 -IL2 mutein fusion antibody achieving selective tumor Treg depletion

Cancer Research2025-04-21